The Phoenix at-home acoustic wave device

Our assessment

Three words get used interchangeably in this market and they mean entirely different things. FDA *approved* means the agency reviewed evidence of safety and effectiveness. FDA *cleared* means it was shown substantially equivalent to an existing device. FDA *registered* means the company filled in a form listing itself and its product — no review of anything, and the FDA is explicit that registration does not denote approval.

The sellers of this device use the third word. A syndicated press release uses the first. We looked for either of the first two in the FDA’s own databases and found neither: no 510(k) clearance under the manufacturer’s name, and no establishment registration under four spellings of it. Databases lag and companies restructure, so we will not tell you the registration does not exist — we will tell you we went looking in the obvious places and did not find it, and that a “98% success rate” from a reseller has no visible arithmetic behind it at all.

Now the part that matters more than the paperwork, because it would matter even if every regulatory claim checked out.

Shockwave therapy for erectile dysfunction has a real evidence base, and that evidence belongs to *focused* machines — electrohydraulic or electromagnetic devices that converge a wave at a defined depth, producing the sharp energy spike and negative-pressure phase thought to drive new vessel growth. Radial pressure-wave devices disperse energy from the point of contact, are far cheaper to build, and as one urology group puts it, “stay at the skin level and will not be effective.”

Home devices sit at the shallow end of that divide by physics and by price. A physician review of this specific product found the company “do not provide any scientific evidence to support their claims or they reference studies that use medical, in-office shockwave devices”, and concluded that home units “cannot stimulate the necessary biological processes that lead to better erections”. That is the whole problem in one sentence: the studies are real, and they are somebody else’s.

It is worth being fair about the ceiling here. Even in clinics, using properly focused equipment, this is not settled treatment. Hartford Hospital, citing the Sexual Medicine Society of North America, notes there is not yet sufficient human clinical data, that “long-term results and side effects are not well-known”, and advises against “the temptation, and high prices, of quick-fix treatments lacking federal regulatory agency approval”. If the clinical version is still provisional, a consumer version with no trial of its own is not a shortcut to it.

The same physician review found no sign the device is harmful, and we have no reason to contradict that. This is not a safety warning. It is nine hundred dollars for a device that has not been shown to do the thing it is sold for — against about a dollar a tablet for a medicine that has.

The cost that does not appear on the invoice is the one we would actually worry about. A man who buys a device instead of an appointment has treated a symptom that is frequently the first sign of vascular disease with a gadget that examines nothing. That is the expensive outcome, and it is not the $900.